Our clinical development pipeline features three drug candidates, each with distinct, well defined mechanisms of action for attacking cancer. Our pipeline includes two potential best-in-class drug candidates with validated targets – a HDAC inhibitor and a PI3K delta inhibitor – as well as a novel mitochondrial inhibitor with promising anti-cancer activity.
For a closer look at our emerging pipeline of drug candidates, please visit our website at www.meipharma.com/our-programs.
Pracinostat HDAC InhibitorLearn More
Pracinostat has been designated a Breakthrough Therapy by the FDA in combination with azacitidine for the treatment of patients with newly diagnosed AML who are ≥75 years of age or unfit for intensive chemotherapy. Read More
Acute Myeloid LeukemiaNewly diagnosed, ≥75 years or unfit
Myelodysplastic SyndromeIntermediate-2 & high-risk
Myelofibrosis*Front Line & Relapsed/Refractory
ME-401 PI3K Delta InhibitorLearn More
ME-401 is a next-generation oral PI3K delta inhibitor that has the potential for a superior pharmacokinetic profile and an improved therapeutic window compared to other drugs in its class. Read More
B-Cell MalignanciesRecurrent CLL or follicular NHL
Cancer Metabolism Program
ME-344 Mitochondrial InhibitorLearn More
ME-344 displays a novel mechanism of action with evidence of mitochondrial-specific effects in cancer cells, including enhanced anti-tumor activity when combined with a VEGF inhibitor such as Avastin®. Read More